Mitochondria and Autism Treatment
Mol Syndromol 2011;2:50-52 51 for treatment of autism. Therefore, there is an urgent need to find new solutions for autism treatment.
On the other hand, glutamate neurotoxicity [Harada et al., 2010] and excitotoxicity inflammation [Chauhan and Chauhan, 2006] are reported in autism. Moreover, glutamate synthesis inhibition decreases the neurotoxic activity in autism [Maezawa and Jin, 2010] . Meanwhile, the activation of the NMDA receptor may increase the NO level [Horn et al., 2002] . Cell death due to NMDA receptor agonists is reduced by blockade of NO synthesis [Kollegger et al., 1993] . Neuroinflammation, excitotoxicity, and oxidative stress are suggested as possible targets for treatment of autism [Ghanizadeh, 2010a [Ghanizadeh, , b, 2011a . The mPTP is probably involved in neuronal injury due to excitotoxicity [Schinder et al., 1996] . Moreover, NO causes the release of calcium from mitochondria and induces intracellular calcium release by mPTP opening [Horn et al., 2002] . This leads to excitotoxicity.
Olesoxime is from the family of cholesterol-oximes that binds to some specific outer mitochondrial membrane proteins and prevents permeability transition pore opening mediated by oxidative stress [Bordet et al., 2010] . The neuroprotective effect of olesoxime is based on targeting mitochondria. The orally active compound of olesoxime is tolerated well. Complement 1q binding protein also prevents the mPTP opening through binding to cyclophilin D [McGee and Baines, 2010] . These phenomena will protect cells against oxidative stress.
In conclusion, the production of NO is increased [Sweeten et al., 2004] and oxidative stress is enhanced in autism [Mostafa et al., 2010; Palmieri and Persico, 2010] . Moreover, NO increases mPTP opening [Horn et al., 2002] and mitochondrial functioning is impaired in autism [Palmieri and Persico, 2010] . In addition, complement 1q binding protein [McGee and Baines, 2010] and olesoxime prevent permeability transition pore opening mediated by oxidative stress [Bordet et al., 2010] . Therefore, it is hypothesized that complement 1q binding protein or olesoxime may improve the condition of some patients with autism. So, it is worthwhile conducting the translational appropriate animal model studies to assess mitochondrial functioning [Patterson, 2011] that may open up novel possibilities for autism management.
